Email ID
Password
Scrip   
Arena to file obesity drug after it meets Phase III goals
22 September 2009
Katie McQue

Arena Pharmaceuticals' lead product candidate lorcaserin has met the primary endpoint of its second pivotal Phase III trial in obesity. The company plans to file for US approval of the drug in December.

Lorcaserin showed a placebo-adjusted weight loss of 3.1% of the trial participants'...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36